Mirum Pharmaceuticals, Inc.
MIRM
株式のランク
#3223
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
株価
$85.12
最終同期: 2026-10-20
時価総額
$5.53B
変化（1日）
3.50%
変化（1年）
23.39%
国
US
取引 Mirum Pharmaceuticals, Inc. (MIRM)
カテゴリー
Healthcare
Mirum Pharmaceuticals, Inc.（MIRM）のP/B比率
October 2026 時点のP/B比率 TTM: -486.22
Mirum Pharmaceuticals, Inc. の最新の財務報告および株価によると、現在のP/B比率（TTM）は -486.22 です。2023 年末時点でのP/B比率は 4.85 でした。
Mirum Pharmaceuticals, Inc. の P/B 比率の履歴（2018 ～ 2026）
各年末時点のP/B比率
| 年 | P/B比率 | 変化 |
|---|---|---|
| 2026 (TTM) | -486.22 | -5,682.34% |
| 2024 | 8.71 | 79.44% |
| 2023 | 4.85 | -388.93% |
| 2022 | -1.68 | -141.75% |
| 2021 | 4.02 | -258.02% |
| 2020 | -2.55 | -68.43% |
| 2019 | -8.06 | -72.59% |
| 2018 | -29.42 | 0.00% |
同業他社のP/B比率
| 企業 | P/B比率 | P/B比率の差 | 国 |
|---|---|---|---|
| 6.251 | -101.29% |
US
|
|
| 13.2547 | -102.73% |
US
|
|
| 4.208 | -100.87% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -101.27% |
NL
|
